Adenovirus type 4 a
Ended Awarded Last action
- Contract number
- SPE2DP26F1649
- Awardee
-
Teva Pharmaceuticals Usa, Inc. UEI NEN9A34LRHJ5
- Awarding agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Obligated
- $3,950,554
Award facts
- Contract value 100% obligated
- $3,950,553.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- Parsippany, NJ 07054, USA
Award details come from SAM.gov/FPDS.
About this award
The Department of Defense Medical Supply Chain awarded a $3.95 million delivery order to Teva Pharmaceuticals USA, Inc. on January 13, 2026, for the supply of Adenovirus Type 4 vaccine. This firm-fixed-price delivery order, with an ultimate completion date of January 27, 2026, represents another in a series of over 150 awards issued to Teva since 2023 under indefinite delivery contracts with the Defense Logistics Agency Troop Support Medical. The contract carries no set-aside designation and will be performed at Teva's facility in Parsippany, New Jersey. Teva Pharmaceuticals USA, Inc., a subsidiary of Israeli-based Teva Pharmaceutical Industries Ltd., serves as the prime contractor with no subcontractors identified on this award.
This delivery order supports critical military immunization programs and reflects Teva's established role as a national supplier of essential pharmaceuticals to federal healthcare systems. The company's extensive federal contract portfolio demonstrates consistent capability in large-scale vaccine supply, with individual delivery orders typically valued between $152,000 and $2.4 million and completion achieved within one to two weeks of award dates. Beyond vaccine supply, Teva maintains significant indefinite delivery contracts with the Department of Veterans Affairs and Defense Logistics Agency for specialty pharmaceuticals including glatiramer acetate injections and Levalbuterol HCL solution, underscoring the company's critical importance to Department of Defense, Veterans Affairs, Bureau of Prisons, and Indian Health Service medical supply operations.
Quick answers
Who was awarded contract SPE2DP26F1649?
SPE2DP26F1649 was awarded to Teva Pharmaceuticals Usa, Inc. by Medical Supply Chain (Troop Support) on January 13, 2026.
How much is contract SPE2DP26F1649 worth?
The government has obligated $3,950,554 on SPE2DP26F1649.
Is contract SPE2DP26F1649 an order under another contract?
Yes. SPE2DP26F1649 is a delivery order under SPE2DP20D0002, an indefinite delivery contract.
Was contract SPE2DP26F1649 competed?
The extent of competition for SPE2DP26F1649 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award